INVO Fertility Q1 revenue up 23% to $2.0M; net loss widens on warrant charge, balance sheet strengthened

INVO Fertility, Inc.

Revenue $2.02M (+23% YoY); clinic revenue $1.98M (+22%) driven by organic growth and Family Beginnings acquisition.
Net loss from continuing ops $5.5M (incl. $3.8M non-cash warrant remeasurement) vs $1.5M prior year.
Adjusted EBITDA -$1.26M vs -$0.6M; investments in personnel and infrastructure for future clinic expansion.
Eliminated all Series C-2 Preferred ($2.4M) and warrant liabilities ($1.9M); cash rose to $4.9M from $2.1M at Dec 2025.
Stockholders' equity more than doubled to $15.0M (108% increase); total liabilities down 26% to $9.6M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INVO Fertility, Inc. reported first quarter ended March 31, 2026 results: revenue $2,015,225, net income $(5.5) million.

Period: first quarter ended March 31, 2026
Revenue: $2,015,225
Net income: $(5.5) million
Result: reported results

Exact text from the filing

announced financial results for the first quarter ended March 31, 2026. Q1 2026 Financial Highlights (all metrics compared to Q1 2025 unless otherwise noted) ● Revenue was $2,015,225, an increase of 23% compared to $1,637,185. ● Consolidated clinic revenue increased 22% to $1,982,233, compared to $1,621,553. ● Net loss from continuing operations was $(5.5)

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-029517

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.